RealSeq Biosciences Wins NIH Phase II Grant to Advance RNA Fragmentomics
RealSeq Biosciences, a leader in RNA-based diagnostics, has received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) (FAIN# R44HG013284; Federal Award Date: August 15, 2025). This highly competitive, multi-year award provides non-dilutive funding to accelerate the company’s proprietary RNA fragmentomics platform, RiboMarker®, toward commercialization.
The grant follows RealSeq’s successful Phase I program, where the company demonstrated how RNA fragmentomics can uncover hidden disease signatures in liquid biopsy samples. With Phase II support, RealSeq will advance assay development in oncology and infectious disease, expand partnerships with leading clinical, commercial, and academic collaborators, and prepare its platform for regulatory review and commercial launch.
RealSeq’s fragmentomics technology is designed to analyze RNA fragmentation patterns—information missed by conventional sequencing approaches. By accessing this layer of biological data, the company’s platform aims to transform cancer monitoring, infectious disease detection, and precision medicine, while also offering applications in single-cell biology.
Founded by RNA technology pioneers Sergio Barberan-Soler, PhD, and Sergei Kazakov, PhD, RealSeq combines strong intellectual property with deep scientific expertise. With NIH backing, the company is well-positioned to redefine the future of RNA diagnostics and biomarker discovery.
